Borrow Market Tightening for SLS
Data from Interactive Brokers indicates that SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is experiencing a notable increase in borrowing costs. As of the latest update, the cost-to-borrow (CTB) fee has reached 10.97%. This elevated rate reflects a scarcity of lendable shares, with only 35,000 shares currently reported as available for short sellers.
Implications for Short Sellers
Investors should note that this data is sourced specifically from Interactive Brokers and represents a snapshot of their internal lending pool. A borrow fee in the double digits often signals that the stock is becoming 'hard-to-borrow,' which can increase the risk of a short squeeze if positive catalysts emerge. Traders should monitor these fee fluctuations closely, as rapid changes in availability often precede significant price volatility in biotech equities.
Signal data sourced from ChartExchange. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.